Background {#Sec1}
==========

Memory differs between women and men in ways that may meaningfully impact the detection and course of Alzheimer's disease (AD). In particular, women have verbal memory strengths that appear to be sustained early in the disease, despite measurable pathological changes, including fluorodeoxyglucose positron emission tomography (FDG PET) abnormalities \[[@CR1]\], hippocampal volume (HV) loss \[[@CR2]\], and amyloid beta (Aβ) protein accumulation as shown by a positive amyloid PET scan \[[@CR3], [@CR4]\]. This early preserved memory may delay diagnosis \[[@CR5]\], which is troubling given evidence that women---and particularly those with risk factors such as Apolipoprotein ε4 (*APOE* ε*4*) genotype---may decline faster than men, once AD-related cognitive decline has begun \[[@CR6]--[@CR9]\]. The exact timing of women's memory changes in AD remains unknown and a topic of interest \[[@CR10]\].

Memory advantages in women throughout the lifespan could relate to a variety of etiological factors (e.g., \[[@CR9], [@CR11]--[@CR14]\]). Proximally, preservation of memory is expected to be reflected in resilience in neural structures and functions that subserve healthy memory. Although memory relies on a complex network of neural regions interacting effectively, the central role of the hippocampus in episodic memory (for a review, see \[[@CR15]\]) and in AD \[[@CR16]\] makes this structure a natural candidate for underlying neural resilience. Specifically, the hippocampus is critical for memory consolidation, and damage to the hippocampus can lead to decreased ability to learn and recall new information \[[@CR15]\]. In AD, the hippocampus is impacted by pathology early in the disease course, with neurofibrillary tangle buildup beginning in the cornu ammonis 1 (CA1) and subiculum regions and progressing throughout the hippocampus in a predictable fashion \[[@CR16]\].

Previous work from our group has built preliminary support for relatively preserved total and right hippocampal volume (HV) \[[@CR3]\] and right subiculum subfield volume \[[@CR17]\] in women. Specifically, with a trend-level finding, our data suggested that sex moderated the effects of diagnosis and amyloid PET positivity on HV. In women, positive amyloid PET related to smaller HV only at the mild cognitive impairment (MCI) stage, but not in cognitively normal women. The pattern in men was similar, but the differences were not significant \[[@CR3]\]. When we examined these findings by hippocampal subfield, we replicated the effect only within the right subiculum \[[@CR17]\].

Importantly, if sex relates to a time-limited preservation of memory and/or HV in AD, analyses of sex effects should consider both diagnostic trajectory (i.e., normal cognition to MCI to dementia) and presence of biomarkers such as brain amyloid and tau measured by PET or indexed by the cerebrospinal fluid (CSF). This process allows for higher certainty that sex effects are occurring in AD and not general to non-AD cognitive impairment.

Work on sex differences in AD has been done with large, well-characterized study samples, and especially in one study population (the Alzheimer's Disease Neuroimaging Initiative \[ADNI\]). However, a key step in understanding sex differences in AD is exploring whether findings within ADNI replicate in different samples and with different measures.

The current investigation sought to examine whether the effects of AD proteinopathy on memory and hippocampal volume differ based on sex in the Swedish BioFINDER cohort. BioFINDER offers advantages in that it includes a clinically representative sample of patients who were consecutively referred to participating memory clinics and control participants recruited from an ongoing population-based study (the Malmö Diet and Cancer study) \[[@CR18]\]. Both groups on average have levels of education more typical of an aging population than in some other large study samples \[[@CR19]\] and were scanned on the same magnetic resonance (MR) scanner. BioFINDER also includes measures of other cognitive domains, including visuospatial skills, attention, and processing speed skills, allowing for assessment of the specificity of effects to the memory domain. Altogether, these advantages position the BioFINDER \[[@CR20]\] sample well to identify associations between biomarkers of pathological change and cognition.

Based on our prior results \[[@CR3], [@CR17]\], we hypothesized that women would show early relative preservation of memory and HV, such that these variables would be impacted less by AD proteinopathy (Aβ/P-tau+) in CN women than in CN men. In other words, women, but not men, with preclinical AD would show early preservation of these variables. We hypothesized this effect would be specific to memory and not generalized to other cognitive domains. We further hypothesized that at the symptomatic stage, Aβ+ women would no longer show relative preservation of memory and HV, and no sex differences would be observed.

Methods {#Sec2}
=======

Participants {#Sec3}
------------

Participants were selected from the Swedish BioFINDER study, which is a prospective, longitudinal study examining disease mechanisms in AD and other neurodegenerative disorders using several fluid and imaging biomarkers (see <http://biofinder.se> for more information about the study design). For the present study, we included participants with CSF and MRI data from the healthy elderly control cohort (*n* = 250) and all non-demented patients that had been referred to participating memory clinics due to cognitive symptoms (*n* = 432).

The CN elderly participants were consecutively enrolled from a population-based cohort in the South of Sweden (Malmö Diet and Cancer Study \[[@CR18]\]). The inclusion criteria were (1) age ≥ 60 years old, (2) Mini-Mental State Examination (MMSE) \[[@CR21]\] score of 28--30 points, and (3) fluent in Swedish. The exclusion criteria were (1) presence of subjective cognitive impairment, (2) significant neurologic disease (for example, stroke, Parkinson's disease, multiple sclerosis), (3) severe psychiatric disease (for example, severe depression or psychotic syndromes), and (4) dementia or mild cognitive impairment (MCI).

The patients with cognitive symptoms ("symptomatic patients") had all been referred to one of three participating memory clinics in the south of Sweden, mostly from primary care, and consecutively enrolled in BioFINDER based on the following inclusion and exclusion criteria: (1) perceived cognitive decline, (2) did not fulfill Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) \[[@CR22]\] criteria for Major Neurocognitive Disorder (dementia), as assessed by a memory clinic physician, (3) had a MMSE score of 24 to 30 points, (4) were aged 60 to 80 years, and (5) were fluent in Swedish. The exclusion criteria were (1) cognitive impairment that could be explained by another condition (other than prodromal dementia), such as brain tumor, (2) severe somatic disease, and (3) refusing lumbar puncture or neuropsychological testing.

The patients were further categorized as having subjective cognitive decline (SCD) (*n* = 186) or MCI (*n* = 246). The MCI classification was based on the results of a comprehensive neuropsychological battery and the clinical assessment of a senior neuropsychologist and two physicians \[[@CR23]\]. Patients with composite *z*-scores of ≤ − 1.5 standard deviations (SD) in at least one cognitive domain were classified as MCI (at least two different tests were used for each cognitive domain). In agreement with the DSM-5 criteria for mild neurocognitive disorders, all subjects with *z*-scores of − 1 to − 1.5 were individually assessed by the neuropsychologist and classified as MCI if their premorbid ability or individual test scores within each domain indicated a significant cognitive decline. Among the MCI participants, 75% were categorized as amnestic MCI and 25% as non-amnestic MCI. The participants with cognitive complaints who did not fulfill the criteria for MCI or dementia were classified as having SCD. Neuropsychological test measures incorporated in the following statistical analyses were not included in the battery used to determine diagnosis.

The study was approved by the ethical review board in Lund, Sweden, and all participants gave their written informed consent.

CSF analysis and classification of Aβ/P-tau status {#Sec4}
--------------------------------------------------

Lumbar puncture (LP) and CSF procedures followed a previously described protocol \[[@CR22]\]. CSF Aβ42 and phosphorylated tau (P-tau) were analyzed using the Elecsys immunoassays on a cobas e601 analyzer at the Clinical Neurochemistry Laboratory, University of Gothenburg, Sweden.

Aβ/P-tau positivity was defined based on a previously defined CSF cut-off (phosphorylated tau/Aβ42 ratio ≥ 0.022). This cutoff has been validated against FDA-approved visual reads of Aβ PET scans with 90% agreement \[[@CR24]\].

MRI procedures and hippocampal volume {#Sec5}
-------------------------------------

All participants were examined using the same MR scanner (3 Tesla Siemens Tim Trio). The MR scanning and imaging procedures have been described previously \[[@CR25]\]. FreeSurfer software (version 5.3) was used to extract data for the total intracranial volume and total HV (left and right).

Memory function {#Sec6}
---------------

The 10-word list from the Alzheimer's Disease Assessment Scale -- cognitive subscale (ADAS-cog) was used to test memory function \[[@CR26]\]. After three learning trials of 10 words (immediate recall) and a distraction task (naming objects and fingers), the participants were asked to recall the 10 words. The number of omissions on the delayed recall task (i.e., total possible recalled---total recalled) constituted the final test score. Commission errors were not analyzed.

Non-memory functions {#Sec7}
--------------------

Semantic fluency was assessed using the animal naming fluency test \[[@CR27]\]. Visuospatial function was assessed with a cube copying task \[[@CR28]\] scored from 0 to 6 points \[[@CR26]\]. Attention and speed were assessed using Trail Making Test Part A (TMT A) \[[@CR29]\] and the Symbol Digit Modalities Test (SDMT) \[[@CR30]\].

Statistical analysis {#Sec8}
--------------------

Groups were compared using the Mann-Whitney Test. A *p* value of \< 0.05 was used to define statistical significance. Several general linear models (GLMs) were used to test the effect of sex on cognitive performance in the presence of AD proteinopathy at different diagnostic stages. First, we examined memory function (delayed recall omissions) as the dependent variable with the independent variables Aβ/P-tau status, diagnostic group, sex, years of formal education, presence of at least one *APOE* ε4 allele, HV, and total intracranial volume. Interaction effects were tested for Aβ/P-tau status, diagnostic group, and sex. This model was also run using animal naming fluency, cube copying, TMT A, and SDMT as dependent variables. Diagnostic group was primarily stratified into CN and symptomatic patients to achieve better statistical power for the primary analyses; in secondary analyses, the symptomatic patients were further stratified into SCD and MCI patients. To further examine sex differences in the effect of AD proteinopathy on memory, we ran GLMs using delayed recall omissions as dependent variable and Aβ/P-tau, age, and education as independent variables. This model was tested separately for men and women in all diagnostic subgroups (primary analyses separately in CN and symptomatic patients, and in secondary analyses with symptomatic patients stratified into SCD and MCI). Here, (Aβ/P-tau+) CN women are referred to as women with preclinical AD, and (Aβ/P-tau+) CN men are similarly referred to as men with preclinical AD.

Next, sex differences in the effect of AD proteinopathy on HV were examined in the different diagnostic groups. Here, we used models with HV as a dependent variable with the independent variables Aβ/P-tau, sex, diagnostic group, age, education, presence of at least one *APOE* ε4 allele, and total intracranial volume. Total HV, left HV, and right HV were used separately as dependent variables. As for the GLMs described above, interaction effects were tested for Aβ/P-tau status, diagnostic group, and sex (as above, diagnostic group was stratified both as CN or symptomatic patient and, in secondary analyses as CN, SCD, or MCI). In the secondary analyses where symptomatic patients were further stratified into SCD and MCI, interaction effects were analyzed with Mann-Whitney tests due to smaller sample sizes and skewed distributions. All statistical analysis was performed using R version 3.4.4 (The R Foundation for Statistical Computing).

Results {#Sec9}
=======

Demographics {#Sec10}
------------

Of 682 participants, 350 were women, 241 were Aβ/P-tau+, and 267 were *APOE* ε4 carriers. Regarding diagnosis, 250 were CN and 432 had cognitive symptoms (of which 186 had subjective and 246 objective symptoms). Average age was 71.7 (SD = 5.5). Of CN participants, 152 were women, 67 were *APOE* ε4 carriers (39 women), and 45 were Aβ/P-tau+ (29 women). Of symptomatic patients, 198 were women, 200 were *APOE* ε4carriers (90 women), and 196 were Aβ/P-tau+ (88 women). See Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"} for additional demographic and descriptive information. Table 1Means and standard deviations by diagnostic group (cognitively normal or symptomatic), sex, and Aβ/P-tau status for demographics; memory and global cognitive scores, hippocampal and total intracranial volumes; and number of APOE ε4 carriersCognitively normal (CN)Symptomatic patientsMenWomenMenWomenAβ/P-tau+Aβ/P-tau−Aβ/P-tau+Aβ/P-tau−Aβ/P-tau+Aβ/P-tau−Aβ/P-tau+Aβ/P-tau−(*N* = 16)(*N* = 82)(*N* = 29)(*N* = 123)(*N* = 108)(*N* = 126)(*N* = 88)(*N* = 110)Age74.38 (4.40) ^b^72.40 (4.58) ^b^74.38 (4.34) ^b^74.03 (5.31) ^b^72.43 (5.18) ^a,b^69.84 (5.61) ^a,b^71.12 (5.05) ^a,b^69.08 (5.68) ^a,b^Education14.12 (4.29)12.17 (3.58)11.97 (4.23)12.08 (3.30)11.65 (3.58)11.63 (3.69)11.51 (3.31)12.18 (3.28)ADAS Delayed Word Recall Omissions (/10)3.31 (2.39)2.12 (1.63)2.07 (2.17)1.74 (1.91)6.00 (2.39)4.90 (2.37)6.50 (2.40)3.50 (2.46)MMSE total score28.69 (0.87)29.09 (0.98)29.17 (0.76)28.91 (0.99)27.19 (1.80)28.11 (1.78)27.1 (1.78)28.31 (1.57)Total intracranial volume1.7 × 10^6^ (1.5 × 10^5^)1.7 × 10^6^ (1.3 × 10^5^)1.5 × 10^6^ (9.7 × 10^4^)1.5 × 10^6^ (1.1 × 10^5^)1.7 × 10^6^ (1.2 × 10^5^)1.7 × 10^6^ (1.4 × 10^5^)1.5 × 10^6^ (1.2 × 10^5^)1.5 × 10^6^ (1.2 × 10^5^)Total hippocampal volume7.8 × 10^3^ (1.0 × 10^3^)7.7 × 10^3^ (1.1 × 10^3^)7.0 × 10^3^ (8.9 × 10^2^)7.1 × 10^3^ (9.1 × 10^2^)6.8 × 10^3^ (1.1 × 10^3^)7.4 × 10^3^ (1.3 × 10^3^)6.3 × 10^3^ (1.1 × 10^3^)7.1 × 10^3^ (1.1 × 10^3^)*APOE* ε4 carriers12 ^a^16 ^a^16 ^a^23 ^a^76 ^a^34 ^a^63 ^a^27 ^a^*Abbreviations*: *Aβ/P-tau+* amyloid beta/P-tau positive, *ADAS* Alzheimer's Disease Assessment Scale, *APOE* apolipoprotein E, *MMSE* Mini-Mental State Examination^a^Differs by Aβ/P-tau+ within diagnostic group, *p* \< 0.001^b^Differs by sex within diagnostic group, *p* \< 0.05Significant differences in these variables by Aβ/P-tau status and sex within each diagnostic group are indicated by superscript Table 2Means and standard deviations by symptomatic diagnostic group (subjective cognitive decline or mild cognitive impairment), sex, and Aβ/P-tau status for demographics; memory and global cognitive scores, hippocampal and total intracranial volumes; and number of APOE ε4 carriersSubjective cognitive decline (SCD)Mild cognitive impairment (MCI)MenWomenMenWomenAβ/P-tau+Aβ/P-tau−Aβ/P-tau+Aβ/P-tau−Aβ/P-tau+Aβ/P-tau−Aβ/P-tau+Aβ/P-tau−(*N* = 34)(*N* = 51)(N = 25)(*N* = 76)(*N* = 74)(*N* = 75)(*N* = 63)(*N* = 34)Age72.59 (5.37) ^a,b^70.22 (5.46) ^a,b^70.63 (4.84) ^a,b^69.78 (5.69) ^a,b^72.35 (5.13) ^a^69.59 (5.74) ^a^71.37 (4.88) ^a^69.76 (5.52) ^a^Education11.71 (3.84) ^a^13.00 (3.59) ^a^11.60 (3.33) ^a^11.97 (3.30) ^a^11.62 (3.49) ^a^10.71 (3.48) ^a^11.44 (3.07) ^a^10.47 (3.13) ^a^ADAS Delayed Word Recall Omissions (/10)4.12 (1.89)3.38 (1.89)5.06 (3.02)4.73 (2.80)6.91 (2.06) ^a^5.92 (2.10) ^a^7.43 (1.81) ^a^5.24 (2.69) ^a^MMSE total score28.35 (1.54)28.92 (1.29)27.88 (1.88)27.74 (1.73)26.65 (1.67)27.56 (1.85)26.84 (1.79)27.62 (1.88)Total intracranial volume1.7 × 10^6^ (1.1 × 10^5^)1.7 × 10^6^ (1.3 × 10^5^)1.5 × 10^6^ (1.1 × 10^5^)1.5 × 10^6^ (1.2 × 10^5^)1.7 × 10^6^ (1.3 × 10^5^)1.7 × 10^6^ (1.4 × 10^5^)1.5 × 10^6^ (1.2 × 10^5^)1.5 × 10^6^ (1.2 × 10^5^)Total hippocampal volume7.2 × 10^3^ (1.1 × 10^3^)7.7 × 10^3^ (1.3 × 10^3^)6.8 × 10^3^ (1.3 × 10^3^)6.7 × 10^3^ (1.1 × 10^3^)6.7 × 10^3^ (1.1 × 10^3^)7.2 × 10^3^ (1.3 × 10^3^)6.1 × 10^3^ (1.0 × 10^3^)6.6 × 10^3^ (1.2 × 10^3^)*APOE* ε4 carriers21 ^a^14 ^a^17 ^a^21 ^a^55 ^a^20 ^a^46 ^a^6 ^a^*Abbreviations*: *Aβ/P-tau+* amyloid beta/P-tau positive, *ADAS* Alzheimer's Disease Assessment Scale, *APOE* apolipoprotein E, *MMSE* Mini-Mental State Examination^a^Differs by Aβ/P-tau+ within diagnostic group, *p* \< 0.05^b^Differs by sex within diagnostic group, *p* \< 0.05Significant differences in these variables by Aβ/P-tau status and sex within each diagnostic group are indicated by superscript

Among CN participants, Mann-Whitney tests showed that age and education did not differ by amyloid status (age: *W* = 3955.5, *p* = 0.13; education: *W = 4433.0, p* = 0.68), but a greater percentage of Aβ/P-tau+ versus Aβ/P-tau− CN individuals were *APOE* ε4 carriers (*W =* 2482.0, *p* \< 0.001). Mann-Whitney tests also revealed CN women were older (*W =* 6439.5, *p* = 0.05), but CN men and women did not differ in education level (*W =* 7969.0, *p* = 0.35) or number of *APOE* ε4 carriers (*W =* 7490.0, *p* = 0.57) (see Table [1](#Tab1){ref-type="table"}).

Within symptomatic participants, Mann-Whitney tests showed that Aβ/P-tau+ individuals were older (*W =* 17,639.0, *p* \< 0.001) and were more likely to be *APOE* ε4 carriers (*W =* 12,647.0, *p* \< 0.001). Symptomatic Aβ/P-tau+ versus Aβ/P-tau− individuals did not differ in education level (*W =* 23,862.0, *p* = 0.36). Mann-Whitney tests also revealed men and women with cognitive symptoms did not differ in education level (*W =* 21,386.0, *p* = 0.30) or number of *APOE* ε4 carriers (*W =* 23,418.0, *p* = 0.69), but men were older (*W =* 25,686.0, *p* = 0.05) (see Table [1](#Tab1){ref-type="table"}).

Secondary Mann-Whitney analyses examining differences within SCD and MCI individuals showed that within SCD, Aβ/P-tau+ individuals were older (*W =* 2852.5, *p* \< 0.01), more likely to be *APOE* ε4 carriers (*W =* 2345.0, *p* \< 0.001), and had lower education levels (*W =* 4576.5, *p* = 0.015). Mann-Whitney tests revealed men and women with SCD did not differ in education level (*W =* 414,105.0, *p* = 0.68) or number of *APOE* ε4 carriers (*W =* 4382.00, *p* = 0.53), but men were older (*W =* 5094.5, *p* = 0.03). For MCI individuals, Aβ/P-tau+ individuals were older (*W =* 5778.0, *p* \< 0.01), more likely to be *APOE* ε4 carriers (*W =* 3743.0, *p* \< 0.001), and had higher education levels (*W =* 6019.5, *p* = 0.03). Mann-Whitney tests showed men and women with SCD did not differ in education level (*W =* 6814.0, *p* = 0.83), number of *APOE* ε4 carriers (*W =* 6990.0, *p* = 0.62), or age (*W =* 7455.5, *p* = 0.67) (see Table [2](#Tab2){ref-type="table"}).

Interactive effects of sex, diagnosis, and amyloid status on delayed verbal recall {#Sec11}
----------------------------------------------------------------------------------

The GLM with sex, diagnosis (CN or symptomatic), Aβ/P-tau+, and their interactions predicting delayed recall omissions on the ADAS word recall task showed a significant three-way interaction of Aβ/P-tau+, diagnosis, and sex (*p* \< 0.001) as well as a two-way interaction of Aβ/P-tau+ and sex (*p* = 0.008). These interactions were observed in a model including age, education, *APOE* ε4 status, and total HV as covariates (Table [3](#Tab3){ref-type="table"}). A secondary analysis that grouped diagnoses as CN, SCD, or MCI showed a similar three-way interaction of Aβ/P-tau+, diagnosis, and sex (*p* = 0.01; see Table [4](#Tab4){ref-type="table"}). Table 3Results for regression models with sex, diagnosis (cognitively normal or symptomatic), Aβ/P-tau status, and their interactions predicting recall omissions on the ADAS word recall task and total hippocampal volumeVariableADAS 10 Word Recall OmissionsEstimate*p*Intercept0.560.704Diagnosis (0 = CN, 1 = symptomatic)2.51\< 0.001Age0.00880.61Education−0.107\< 0.001Total intracranial volume (*z*-scored)0.2250.039Sex (0 = male)0.220.74Hippocampal volume (*z*-scored)−0.781\< 0.001APOE ε4 Genotype (0 = no ε4)0.0490.79CSF Aβ/P-tau positivity (Aβ/P-tau+) (0 = not Aβ/P-tau+)1.970.10Aβ/P-tau+ × diagnosis−0.630.33Aβ/P-tau+ × sex−4.050.008Diagnosis × sex−0.760.06Aβ/P-tau+ × diagnosis × sex2.92\< 0.001VariableTotal hippocampal volumeEstimate*p*Intercept10,938\< 0.001Diagnosis (0 = CN, 1 = symptomatic)− 547\< 0.001Age−82.8\< 0.001Education5.000.64Total intracranial volume (*z*-scored)0.0019\< 0.001Sex (0 = male)− 1660.59APOE ε4 Genotype (0 = no ε4)20.70.81Aβ/P-tau+ (0 = not Aβ/P-tau+)4530.42Aβ/P-tau+ × diagnosis− 4010.18Aβ/P-tau+ × sex−72.10.92Diagnosis × sex77.80.68Aβ/P-tau+ × diagnosis × sex−76.00.84Abbreviations: *Aβ/P-tau+* amyloid beta/P-tau positivity, *ADAS* Alzheimer's disease Assessment Scale, *APOE* apolipoprotein E, *CN* cognitively normal, *CSF* cerebrospinal fluid, *MMSE* Mini-Mental State Examinationsignificant p values had been bolded (*p* \< .05) Table 4Results for secondary regression model with sex, diagnosis (cognitively normal, subjective cognitive decline, or mild cognitive impairment), Aβ/Ptau status, and their interactions predicting recall omissions on the ADAS word recall taskVariableADAS 10 Word Recall OmissionsEstimate (CI)*p*Intercept−.986 (−2.14--4.90)0.454Diagnosis (1 = CN, 2 = SCD, 3 = MCI)1.75 (1.44--2.07)*\< 0.001*Age0.03 (−0.00--0.60)*0.035*Education−0.07 (−0.12 to − 0.03)*\< 0.001*Total intracranial volume (*z*-scored)0.081 (−0.12--0.28)0.419Sex (0 = male)−0.40 (−1.31--0.51)0.392Hippocampal volume (*z*-scored)− 0.517 (− 0.70 to − 0.34)*\< 0.001APOE* ε4 genotype (0 = no ε4)0.01 (− 0.33--0.35)0.96CSF Aβ/P-tau positivity (Aβ/P-tau+) (0 = not Aβ/P-tau+)0.64 (− 0.77--2.04)0.376Aβ/P-tau+ × diagnosis0.03 (− 0.54--0.60)0.92Aβ/P-tau+ × sex− 1.50 (− 3.32--0.32)0.108Diagnosis × sex−0.20 (− 0.65--0.26)0.398Aβ/P-tau+ × diagnosis × sex1.03 (0.25--1.82)*0.01*Note: Estimates, confidence intervals, and *p* values were calculated for each regression modelAbbreviations: *Aβ/P-tau+* amyloid beta/P-tau positive, *ADAS* Alzheimer's Disease Assessment Scale, *APOE* apolipoprotein E, *CSF* cerebrospinal fluid, *MMSE* Mini-Mental State Examination

Parsing this interaction effect indicated that women but not men showed a significant interaction between amyloid status and diagnosis (subsample with men, *p* = 0.42; subsample with women, *p* \< 0.001). Specifically, Aβ/P-tau+ did not impact delayed recall memory in women in the CN group (*p* = 0.45, adjusted for age and education), but related to poorer memory in symptomatic women (*p* \< 0.001). In contrast, Aβ/P-tau+ was associated with poorer memory performance both in CN men (*p* = 0.02) and in symptomatic men (*p* = 0.003) adjusted for age and education (Fig. [1](#Fig1){ref-type="fig"}). A secondary analysis, splitting the symptomatic group into SCD and MCI, showed Aβ/P-tau+ related to poorer memory both in female SCD (*p* = 0.02) and MCI (*p* \< 0.001) and in male SCD (*p* = 0.057) and MCI (*p* = 0.006) (see Additional file [1](#MOESM1){ref-type="media"}: Figure S1). Fig. 1Comparison of the Aβ/P-tau effect on memory in men and women. Comparison of 10 word delayed recall performance in Aβ/P-tau+ and Aβ/P-tau− participants, stratified by sex, in **a** healthy controls and **b** patients with cognitive symptoms. Comparisons were adjusted for age and education. Further comparison among the symptomatic patients (SCD and MCI) is shown in Additional file [1](#MOESM1){ref-type="media"}: Figure S1

Interactive effects of sex, diagnosis, and amyloid status on verbal semantic fluency, visuospatial function, and attention/processing speed {#Sec12}
-------------------------------------------------------------------------------------------------------------------------------------------

The above models with sex, diagnosis (CN or patients with cognitive symptoms), Aβ/P-tau+, and their interactions were also tested for predicting performance on verbal semantic fluency (animal naming fluency), visuospatial function (cube copying), and attention/processing speed (TMT A and SDMT). The models were, as for memory function, adjusted for age, education, *APOE* ε4 status, and total HV. In contrast to using memory performance as outcome, the three-way interaction of Aβ/P-tau+, diagnosis, and sex was not significant for verbal fluency (*p* = 0.11), visuospatial function (*p* = 0.60), or attention/processing speed (TMT A, *p* = 0.86; SDMT, *p* = 0.96).

Interactive effects of sex, diagnosis, and amyloid status on hippocampal volume {#Sec13}
-------------------------------------------------------------------------------

In contrast to the memory analysis, the GLM with sex, diagnosis, Aβ/P-tau+, and their interactions predicting total HV did not show a significant interaction of Aβ/P-tau+, diagnosis, and sex (*p* = 0.91). However, diagnosis, age, and total intracranial volume (ICV) showed significant main effects on HV. Specifically, older age was associated with smaller HV (*p* \< 0.001), as was having cognitive symptoms (*p* \< 0.001). Greater total intracranial volume was associated with greater HV (*p* \< 0.001) (see Table [3](#Tab3){ref-type="table"} for details). Similar significant main effects and similar lack of interaction effects were seen when grouping diagnoses into CN, SCD, and MCI and when left and right HV were examined separately (interaction: left: *p* = 0.68; right: *p* = 0.85; total *p* = 0.91) (see Additional file [2](#MOESM2){ref-type="media"} for details).

Discussion {#Sec14}
==========

The current study showed that women with AD proteinopathy (Aβ/P-tau+) showed no memory impairment relative to Aβ/P-tau− women prior to self-reporting concerns about their cognition (i.e., only in the CN group). In contrast, men with Aβ/P-tau+ performed more poorly on the verbal memory task than Aβ/P-tau− men, regardless of whether they experienced cognitive symptoms or not. As hypothesized, similar effects were not seen on tests of other cognitive domains. Analyses examining HV showed no significant interactive effects of sex, diagnosis, and Aβ/P-tau+, and diagnosis alone of these three factors showed a significant main effect on HV.

These results supported our hypotheses about sex-based preservation of verbal memory. Namely, Aβ/P-tau+ CN women (i.e., women with preclinical AD) appear to have verbal memory reserve or resilience in the presence of measurable AD-related disease burden. This result is consistent with our and others' work showing that women's memory has some early resilience to a number of markers of AD burden, including abnormal brain metabolism \[[@CR1]\], hippocampal atrophy \[[@CR2]\], and positive amyloid PET \[[@CR3], [@CR4]\]. Importantly, the current results replicate our prior findings in a separate sample that incorporated different measures of memory and amyloid proteinopathy, supporting the robustness of this finding \[[@CR3]\]. Early verbal memory preservation may have implications for how normal cognition is defined in research and in clinical trials. For example, it may be more critical when examining longitudinal or interventional outcomes to define baseline group membership using biomarkers in combination with cognitive testing, if women are included in the sample. From a clinical diagnosis perspective, this finding emphasizes the importance of cognitive baseline assessment, as early neuropsychological testing may be able to identify women who have normal cognition yet have lost some memory functioning over time. Employing memory assessments that are not purely verbal may also be important for increasing validity of memory assessment across sexes.

Supplementary analyses showed that verbal memory was not preserved in Aβ/P-tau+ women with SCD as compared to Aβ/P-tau− women with SCD. In addition, in the SCD group, women no longer outperformed men in verbal memory. This pattern suggests that among women with increased risk for AD dementia (Aβ/P-tau+), memory reserve or resilience is limited to CN women with no cognitive concerns. This finding is consistent with studies showing that SCD is associated with positive AD biomarkers and longitudinal cognitive decline (\[for recent review on SCD, see \[[@CR31]\]), as well as with research showing that AD proteinopathy in the context of SCD is a strong predictor of decline \[[@CR32]\]. However, this finding stands in contrast to research within the ADNI sample, showing that women outperform men on verbal memory tasks despite mild to moderate levels of AD-related burden \[[@CR1], [@CR2]\]. It is possible that the current finding relates to Aβ/P-tau+ women with SCD in the BioFINDER sample having more than a moderate level of AD-related disease burden. Alternatively, the finding may relate to other differences between samples. Specifically, the greater education levels---and thereby greater general cognitive reserve---in the ADNI sample may have an impact. On the other hand, in the BioFINDER sample, individuals with SCD have been referred to a memory specialist due to cognitive symptoms, whereas in ADNI, individuals with SCD reported symptoms when queried. In this context, our findings suggest that for women seeking a memory specialist, SCD could be not only a marker of risk, but also an indicator that subclinical memory changes are already measurable on cognitive testing. This suggestion is in part consistent with very recent work in other cohorts \[[@CR33], [@CR34]\].

The current study did not confirm hypotheses about sex-specific HV preservation. Previously, we have shown in the ADNI sample that CN women with positive amyloid PET studies show no difference in total HV and subiculum subfield volume, compared to CN women with negative amyloid PET, but that volumetric decrements are observed in amyloid-positive women at the MCI stage \[[@CR3], [@CR17]\]. Reasons for lack of replication are unclear but could include slight differences in methodology or sample composition, such as inclusion of CN and symptomatic groups in the present analysis as well as differences in the biomarkers used to define the presence of proteinopathy. Lack of replication emphasizes the need for additional research on how this structure---with known developmental \[[@CR35]\], aging-related \[[@CR36], [@CR37]\], and neurochemical sex differences \[[@CR38]\]---does or does not show patterns of dysfunction and atrophy that differ by sex in AD. In addition, this finding underscores the importance of considering other neural underpinnings of early sex-based memory preservation and later decline.

As important context, there are known sex by *APOE* ε4 interactive effects, with evidence for more deleterious effects of *APOE* ε4 on cognition, hippocampal structure, brain function at rest, and tau pathology in women than men (\[[@CR6], [@CR39]\], for a recent review see \[[@CR40]\]). The present analysis showed that men and women did not differ in number of *APOE* ε4 carriers and also controlled for effects of *APOE* ε4. Despite these efforts to show our findings were not driven by *APOE* ε4 status, adding *APOE* ε4 as an interaction term was beyond the scope of the present analysis due to limited power. Further work is needed on how memory reserve presents over the AD spectrum in women with *APOE* ε4.

Limitations of this analysis include having a smaller sample size than studies that combine across cohorts, which is particularly relevant when evaluating complex interactions. Although the current study in part replicates prior work by our group \[[@CR3]\], the challenges of complex interactions and multiple comparisons mean that wider replication is important to ensure generalizable conclusions. Expanding the analysis to additional regions of interest will also be important for generalizability. The sample included is also majority white, and research in diverse samples will be key to generalizing the findings to all women. The current analysis was also cross-sectional in nature, limiting ability to interpret memory findings as true losses of function over time. In contrast, the present study has strengths in that participants are more representative of the general aging population than in some other cohorts \[[@CR18], [@CR19]\], were more thoroughly assessed and diagnosed, and have had brain imaging conducted on the same MRI magnet.

Conclusions {#Sec15}
===========

In conclusion, this study shows relative preservation of verbal memory in the presence of AD proteinopathy, limited to women with normal cognition, and not in women with reported or measured memory symptoms. This resilience was specific to memory and was not present for other cognitive functions. Future studies should examine other potential neural sources of sex-based early memory preservation, conduct additional multi-cohort analyses of complex sex-based interactive effects---including longitudinally---and examine the practical effects of sex differences in memory on clinical diagnosis and clinical trial inclusion and outcomes.
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**Additional file 1:** **Figure S1.** Comparison of the Aβ/P-tau effect on memory in men and women. Comparison of 10 word delayed recall performance in Aβ/P-tau+ and Aβ/P-tau- participants, stratified by sex, in patients with A. subjective cognitive decline, and B. mild cognitive symptoms. **Additional file 2:** Regression Predicting Hippocampal Volumes with Cognitively Normal, Subjective Cognitive Decline, and Mild Cognitive Impairment Groups. This additional file contains a table summarizing the results of a regression predicting hippocampal volumes separated by diagnostic group.

AD

:   Alzheimer's disease

ADAS-Cog

:   Alzheimer's Disease Assessment Scale -- cognition

ADNI

:   Alzheimer's Disease Neuroimaging Initiative

Aβ

:   Amyloid beta

CN

:   Cognitively normal

CSF

:   Cerebrospinal fluid

FDG PET

:   Fluorodeoxyglucose positron emission tomography

GLM

:   General linear models

ICV

:   Total intracranial volume

LP

:   Lumbar puncture

MCI

:   Mild cognitive impairment

MMSE

:   Mini-Mental State Examination

MR

:   Magnetic resonance

P-tau

:   Phosphorylated Tau

SCD

:   Subjective cognitive decline
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